CERo Therapeutics Holdings Inc. has provided a clinical update on its ongoing Phase 1 clinical trial of CER-1236, an investigational cellular immunotherapy for patients with acute myeloid leukemia (AML). The trial, known as CertainT-1, has completed the dose-limiting toxicity (DLT) observation period for the first patient in the second cohort, who received a dose level of 4e6 cells/kg, four times higher than the dose administered to the first cohort. Additionally, a second patient in the first cohort has received a fourth additional dose and remains on study. The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations. Results from the study have not yet been presented, and enrollment and dosing are ongoing with continued safety monitoring.